• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Comp Immunol Microbiol Infect Dis . Potential of Clostridium perfringens sialidase as a novel antiviral agent against avian influenza H5N1 infection

tetano

Editor, Senior Moderator
Comp Immunol Microbiol Infect Dis


. 2025 Jun 26:121:102373.
doi: 10.1016/j.cimid.2025.102373. Online ahead of print. Potential of Clostridium perfringens sialidase as a novel antiviral agent against avian influenza H5N1 infection in BALB/c mice

Otto Sahat Martua Silaen[SUP] 1 [/SUP], Silvia Tri Widyaningtyas[SUP] 2 [/SUP], Christian Marco Hadi Nugroho[SUP] 3 [/SUP], Ryan Septa Kurnia[SUP] 3 [/SUP], Muhammad Ade Putra[SUP] 3 [/SUP], Agustin Indrawati[SUP] 4 [/SUP], Desak Gede Budi Krisnamurti[SUP] 5 [/SUP], Amin Soebandrio[SUP] 6 [/SUP]



Affiliations
Abstract

The public health concern about H5N1 avian influenza persists because of its lethal nature and its capability to spread between different species and its growing resistance to conventional antiviral medications. The antiviral drug potential of sialidases from Clostridium perfringens remains under investigation because these enzymes can strip sialic acid from viral surfaces which prevents viral attachment to host cells. This study aimed to determine the antiviral effects of C. perfringens sialidase on H5N1-infected BALB/c mice through both preventive and curative treatment protocols. The mice received intranasal sialidase at two concentrations of 187.5 mU/ml and 375 mU/ml for three consecutive days either before viral exposure or after viral challenge. The study included weight tracking and ELISA tests to measure lung tissue viral antigens as well as lung tissue histopathology and IL-6 and TNF-α expression analysis. The treatment with 375 mU/ml sialidase twice proved most effective in maintaining physiological function and reducing viral load and lung tissue damage. The treatment results demonstrated that it reduced inflammatory response by lowering IL-6 and TNF-α expression levels. The research proves that C. perfringens sialidase exhibits antiviral and immunomodulatory actions when used in vivo. The curative outcome depends heavily on treatment dose and frequency which will impact future implementation. The antiviral properties of C. perfringens sialidase make it a promising therapeutic option for treating influenza virus strains that are resistant to drugs.

Keywords: Antiviral; Avian influenza; Clostridium perfringens; Mice; Sialidase.

 
Back
Top Bottom